Stock Ratings / Health Care / CANF / insiders

ADXN (57) XBIO (47) APUS (43) PULM (36) ⌘ Pro Terminal →

Can-Fite Biopharma Ltd each representing two (2) (CANF) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Are CANF insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CANF leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$1.66 +0.61% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Can-Fite Biopharma Ltd each representing two (2) (CANF) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-12% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CANF)Realized 20D OHLCV Swing Band: ±10.7%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CANF Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CANF)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CANF. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CANF)

✓Walkthrough of CANF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CANF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.96%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.68H $1.70L $1.60C $1.66VOL 22.4K

SUP: $1.55SMA50: $2.26SMA200: $3.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CANF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CANF Butterfly Map → + Track CANF →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -39.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CANF today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CANF. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CANF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CANF)

Health Care Rank #938 of 1016 ⚔️ ADXN vs CANF Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CANF vs. ADXN, XBIO, APUS, PULM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Can-Fite Biopharma Ltd each representing two (2) (CANF) ranks #938 by composite RQD confidence (31/100, grade E) and #946 by equity capitalization ($5.0M). Within this direct 5-issuer industry benchmark cohort, CANF leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. ADXN currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with CANF at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CANF ACTIVE Can-Fite Biopharma Ltd each representing two (2)	E	31/100	—	—	-35.0%	+0.61%	$5.0M	Benchmark Subject
ADXN Addex Therapeutics Ltd	D+	57/100	—	—	—	-1.01%	$5.0M	/adxn-vs-canf →
XBIO Xenetic Biosciences Inc.	D	47/100	—	—	-30.3%	+0.95%	$5.0M	/xbio-vs-canf →
APUS Apimeds Pharmaceuticals US Inc.	D-	43/100	—	—	-6.2%	+4.56%	$5.0M	/apus-vs-canf →
PULM Pulmatrix Inc.	D-	36/100	—	—	-35.0%	-5.67%	$5.2M	/pulm-vs-canf →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001536196

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Can-Fite Biopharma Ltd each representing two (2) (CANF) reported GAAP revenue of $405.0K (-39.9% vs. FY2024 revenue of $674.0K , and -45.5% cumulative change since FY2023) , GAAP net income of -$9.8M, operating cash flow of -$8.9M, and free cash flow of -$9.0M (-17.1% YoY). On the balance sheet, CANF closed FY2025 with $9.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$405.0K	-$9.8M	-$8.9M	-$9.0M	$9.5M	—
FY2024 (FY)	2024-12-31	$674.0K	-$7.9M	-$7.6M	-$7.6M	$9.1M	—
FY2023 (FY)	2023-12-31	$743.0K	-$7.6M	-$8.4M	-$8.4M	—	—

3. CANF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CANF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Can-Fite Biopharma Ltd each representing two (2) (NYSE: CANF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.66 (+0.61% 1D, market cap $5.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CANF ranks #938 in composite RQD confidence.

How does CANF compare to ADXN and XBIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CANF carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ADXN (Addex Therapeutics Ltd) holds a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $5.0M) and XBIO (Xenetic Biosciences Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -30.3%, cap $5.0M). Among the 5-stock peer group, CANF leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CANF?

Per CANF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001536196), Can-Fite Biopharma Ltd each representing two (2) generated $405.0K in revenue (-39.9% YoY), -$9.8M in net income, and -$9.0M in free cash flow against $9.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CANF trading relative to its 50-day, 200-day, and 52-week technical levels?

CANF last traded at $1.66 (+0.61% on volume of 22,039 shares), positioning the stock -26.55% below its 50-day simple moving average ($2.26) and -48.29% below its 200-day simple moving average ($3.21). Across its 52-week range of $1.60 to $12.40, CANF sits at the 0.6% percentile with a 14-day RSI of 23.6 (OVERSOLD (<32)) and an implied next-earnings move of ±10.7% ($1.48 to $1.84).

CANF Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are CANF insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CANF leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: CANF RQD Cockpit CANF 12M Forecast CANF Earnings & Move CANF Dividends & DRIP CANF Insiders & 13F CANF Whale Options CANF Profit Sankey CANF News & Why